Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma [0.03%]
霍奇金淋巴瘤的疾病评估现状及未来策略分析
Brian J Sworder,Alex H Herrera
Brian J Sworder
Emerging treatment paradigms in classic Hodgkin lymphoma (cHL), which increasingly incorporate immunotherapy and response-adapted strategies, have increased the need for more accurate disease assessment tools. PET/CT remains the cornerstone...
Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management [0.03%]
结节性淋巴细胞为主型霍奇金淋巴瘤的发病、病因及治疗
Christopher R DAngelo,James O Armitage,Matthew L Lunning
Christopher R DAngelo
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma subtype, representing a small fraction of Hodgkin lymphoma or an even smaller fraction of B-cell non-Hodgkin lymphoma, depending on the classification schema used. N...
Thomas Lucido,Robert Ryan,Sara Sawicki et al.
Thomas Lucido et al.
This review summarizes contemporary management of Classic Hodgkin Lymphoma in special clinical situations, with a focus on integrating primary clinical trial and observational data to inform individualized treatment decisions. The emphasis ...
Meghana Subramanian,Andrew Evens,Joanna M Rhodes
Meghana Subramanian
Older patients age >60 years with advanced-stage cHL have historically had poorer outcomes, attributed to comorbid conditions, performance status, and chemotherapy intolerance. The use of an anthracycline-based chemotherapy backbone has sho...
Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care [0.03%]
青少年及青年人类经典型霍奇金淋巴瘤患者:以AYA癌症护理为例的综述
Brittany C Kimball,Allison C Rosenthal
Brittany C Kimball
Hodgkin lymphoma is one of the most common cancers in adolescents and young adults (AYAs), a population with distinct biological, clinical, and developmental characteristics. Yet care remains fragmented between pediatric and adult systems c...
Kento Kawai,Neha Akkad,Christopher Flowers
Kento Kawai
Management of relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL) has evolved substantially with the integration of novel targeted and immune-based therapies. Agents such as brentuximab vedotin (BV) and immune checkpoint inhibitors (CP...
Joseph Carmicheal,Charles Enke
Joseph Carmicheal
Radiation therapy (RT) has long been an important part of the history of curative treatment for Hodgkin Lymphoma since the pioneering work of Vera Peters, MD and Henry Kaplan, MD. The contemporary role of radiation therapy in the management...
Kelsey Baron,Boyu Hu
Kelsey Baron
Before 1970, Hodgkin lymphoma (HL) was an often-fatal lymphoma treated with radiation and/or single-agent chemotherapy. In contrast, HL is now a largely curable disease treated with multiagent chemotherapy regimens. In the intervening half-...
Early-Stage Hodgkin Lymphoma [0.03%]
早期霍奇金淋巴瘤
Kishan Patel,Varun Iyengar,Alison Moskowitz
Kishan Patel
Combined modality therapy (CMT; chemotherapy with consolidative radiation) has led to excellent long-term outcomes in patients with early-stage Hodgkin lymphoma. However, despite high cure rates, CMT can lead to significant long-term toxici...
James Armitage,Matthew Lunning
James Armitage